Verastem
NASDAQ: VSTMNeedham, US · Founded 2010 · Massachusetts corporation · 180 employees on LinkedIn · 7 known investors
Find your way into Verastem
359 people in our graph share verified history with the Verastem team — schools, employers, funds. One of them is your warm intro.
Kevin Munnellyunlockedknows AMY C. CAVERS · together at Takeda Oncology (overlapped)
knows the team · via Kymera Therapeutics
×3knows the team · via Mpmcapital
×3knows the team · via Yale School of Medicine
×2knows the team · via Union College
knows the team · via Baylor College of Medicine
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients. The company focuses on oncology therapeutics including small molecules and monoclonal antibodies targeting pathways such as RAS, KRAS, and immune modulation.
Founders & leadership
Verastem was founded in 2010 by Robert Weinberg and RICHARD ALDRICH.
RW
Robert Weinberg
RA
RICHARD ALDRICHCo-founder
AC
AMY C. CAVERSinChief of Engagement & Innovation; SVP, Field Medical, Strategy & Alignment2019–2020Amy C. Cavers is an Executive Officer at Verastem Oncology with over 30 years of experience in biopharmaceutical development, including more than 20 years focused on hematology and oncology. She has held roles in medical affairs, marketing, and business development across global markets, with additional background in ophthalmology, dermatology, neurology, and HIV therapeutics.
CC
CATHY CAREWinChief Organization Effectiveness OfficerCathy Carew is Chief Organization Effectiveness Officer at Verastem Oncology and Principal of HR Collaborative Consulting, where she works on organizational development and executive leadership.
JP
JONATHAN PACHTERinChief Scientific OfficerJonathan Pachter has 25 years of drug discovery experience in large pharmaceutical and biotech companies, with expertise in small molecule and monoclonal antibody development; he has led discovery efforts for multiple oncology and anti-inflammatory candidates and contributed to clinical and regulatory work on cancer therapeutics including Temodar and Tarceva.
RG
ROB GAGNONinBoard Member2022–2026
BS
BRIAN STUGLIKinBoard MemberHe has over 30 years of experience in the pharmaceutical sector, including roles as Vice President and Chief Marketing Officer and Chief Operating Officer for the Oncology Business Unit at Eli Lilly and Company, and holds a Bachelor of Science in Pharmacy from Purdue University.
DP
Dan PatersoninPresident and CEO
RF
ROBERT FORRESTERinPresident, Chief Executive Officer and Director2011–2019
JG
JOHN GREENExecutive
MS
MONICA SINGHinGeneral Counsel2014–2015
JH
JOANNA HOROBINinChief Medical Officer2012–2015Joanna Horobin serves as Executive Officer of Verastem Oncology, a biopharmaceutical company developing cancer therapeutics. She has held independent director positions at multiple biotech companies working on novel treatment approaches.
Investors · 7
Reported raises · per SEC filings
Form D private placements$108.7M disclosed across 3 rounds · 2014–2020
▶$100MraisedMar 2020 · 21 investors · PharmaceuticalsRule 506(c)
▶$100MraisedMar 2020 · 21 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- BRIAN STUGLIKExecutive Officer, Director
- BRUCE WENDELDirector
- ERIC ROWINSKYDirector
- ALISON LAWTONDirector
- TIMOTHY BARBERICHDirector
- MICHAEL KAUFFMANDirector
- DAN PATERSONExecutive Officer
- GINA CONSYLMANDirector
- ROB GAGNONExecutive Officer
- Offering amount
- $100M
- Amount sold
- $100M
- Sales commissions
- $6M
- Placement agents
- H.C.WAINWRIGHT & CO., LLC, JEFFERIES LLC, CANTOR FITZGERALD & CO.
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$4.8MraisedJan 2020 · 4 investors · PharmaceuticalsRule 506(c)
▶$4.8MraisedJan 2020 · 4 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- TIMOTHY BARBERICHDirector
- ALISON LAWTONDirector
- ERIC ROWINSKYDirector
- BRUCE WENDELDirector
- GINA CONSYLMANDirector
- MICHAEL KAUFFMANDirector
- AMY C. CAVERSExecutive Officer
- CATHY CAREWExecutive Officer
- JONATHAN PACHTERExecutive Officer
- ROB GAGNONExecutive Officer
- BRIAN STUGLIKExecutive Officer, Director
- DAN PATERSONExecutive Officer
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$3.9MraisedMar 2014 · 1 investors · BiotechnologyRule 506(b)
▶$3.9MraisedMar 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- MICHAEL KAUFFMANDirector
- ROBERT FORRESTERExecutive Officer, Director
- JOHN GREENExecutive Officer
- CHRISTOPH WESTPHALExecutive Officer, Director
- DAN PATERSONExecutive Officer
- HENRI TERMEERDirector
- JONATHAN PACHTERExecutive Officer
- LOUISE PHANSTIELDirector
- RICHARD ALDRICHDirector
- MONICA SINGHExecutive Officer
- JOANNA HOROBINExecutive Officer
- STEPHEN SHERWIN, M.D.Director
- JOHN K. CLARKEDirector
- ALISON LAWTONDirector
- Offering amount
- $3.9M
- Amount sold
- $3.9M
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Verastem for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Here’s What RBC Capital Has to Say About Verastem (VSTM) - Insider Monkeyinsidermonkey.com · Jul 2026Frequently asked questions
- What does Verastem do?
- Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients. The company focuses on oncology therapeutics including small molecules and monoclonal antibodies targeting pathways such as RAS, KRAS, and immune modulation.
- Who founded Verastem?
- Verastem was founded by Robert Weinberg, RICHARD ALDRICH in 2010.
- Who are Verastem's investors?
- Verastem's investors include Bessemer Venture Partners, Cardinal Partners, Foresite Capital, Lightstone Ventures, Longwood Fund, Oberland Capital, OrbiMed.
- How much funding has Verastem raised?
- Verastem has disclosed $108.7M raised across 3 rounds.
- Where is Verastem headquartered?
- Verastem is headquartered in Needham, US.